Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis.
Détails
ID Serval
serval:BIB_2F7EBB289818
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis.
Périodique
The Lancet. Oncology
Collaborateur⸱rice⸱s
MACH-NC and MARCH Collaborative Groups
Contributeur⸱rice⸱s
Adelstein D.J., Agarwal J., Alfonsi M., Argiris A., Aupérin A., Bacigalupo A., Bar-Ad V., Bartelink H., Beadle B., Belkacemi Y., Bensadoun R.J., Bernier J., Blanchard P., Bourhis J., Bratland Å., Brizel D., Budach V., Budach W., Burtness B., Calais G., Campbell B., Caudell J., Chabaud S., Chamorey E., Chaukar D., Cheugoua-Zanetsie M., Cho K.H., Choussy O., Cruz Hernandez J.J., Denham J.W., Dobrowsky W., Dominello M.M., Driessen CML, Fallai C., Forastiere A.A., Fortpied C., Fountzilas G., Garaud P., Garden A.S., Gery B., Ghadjar P., Ghi M.G., Ghosh Laskar S., Graff-Cailleaud P., Grau C., Gregoire V., Hackshaw A., Haddad E., Haffty B.G., Hansen A., Hay J.H., Hayoz S., Horiot J.C., Hitt R., Jeremic B., Johansen J., Jones C., Julieron M., Kristensen C.A., Kumar S., Lacas B., Langendijk J.A., Lapeyre M., Lartigau E., Licitra L., Le Q.T., Lee J.W., Lee P., Lewin F., Li Y., Lopes A., Lotayef M., Maciejewski B., Mazeron J.J., Mehta S., Michalski W., Moon J., Moon S.H., Moyal E., Nankivell M., Nilsson P., Olmi P., Orecchia R., O'Sullivan B., Overgaard J., Parmar MKB, Petit C., Pignon J.P., Pointreau Y., Posner M.R., Poulsen M.G., Quon H., Racadot S., Rosenthal D.I., Rovea P., Ruo Redda M.G., Sanguineti G., Shenouda G., Simes J., Sharma A., Simon C., Sire C., Skladowski K., Spencer S., Staar S., Strojan P., Stromberger C., Suwinski R., Szutkowski Z., Takácsi-Nagy Z., Tao Y.G., Temam S., Thomson D., Tobias J.S., Torres-Saavedra P., Torri V., Tripcony L., Trotti A., Tseroni V., van Herpen C., van Tinteren H., Vermorken J., Viegas CMP, Vokes E.E., Waldron J., Wernecke K.D., Widder J., Wolf G.T., Wong S.J., Wu J.S., Yamazaki H., Zaktonik B., Zackrisson B., Zhong L.P.
ISSN
1474-5488 (Electronic)
ISSN-L
1470-2045
Statut éditorial
Publié
Date de publication
05/2021
Peer-reviewed
Oui
Volume
22
Numéro
5
Pages
727-736
Langue
anglais
Notes
Publication types: Journal Article ; Meta-Analysis ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
Randomised, controlled trials and meta-analyses have shown the survival benefit of concomitant chemoradiotherapy or hyperfractionated radiotherapy in the treatment of locally advanced head and neck cancer. However, the relative efficacy of these treatments is unknown. We aimed to determine whether one treatment was superior to the other.
We did a frequentist network meta-analysis based on individual patient data of meta-analyses evaluating the role of chemotherapy (Meta-Analysis of Chemotherapy in Head and Neck Cancer [MACH-NC]) and of altered fractionation radiotherapy (Meta-Analysis of Radiotherapy in Carcinomas of Head and Neck [MARCH]). Randomised, controlled trials that enrolled patients with non-metastatic head and neck squamous cell cancer between Jan 1, 1980, and Dec 31, 2016, were included. We used a two-step random-effects approach, and the log-rank test, stratified by trial to compare treatments, with locoregional therapy as the reference. Overall survival was the primary endpoint. The global Cochran Q statistic was used to assess homogeneity and consistency and P score to rank treatments (higher scores indicate more effective therapies).
115 randomised, controlled trials, which enrolled patients between Jan 1, 1980, and April 30, 2012, yielded 154 comparisons (28 978 patients with 19 253 deaths and 20 579 progression events). Treatments were grouped into 16 modalities, for which 35 types of direct comparisons were available. Median follow-up based on all trials was 6·6 years (IQR 5·0-9·4). Hyperfractionated radiotherapy with concomitant chemotherapy (HFCRT) was ranked as the best treatment for overall survival (P score 97%; hazard ratio 0·63 [95% CI 0·51-0·77] compared with locoregional therapy). The hazard ratio of HFCRT compared with locoregional therapy with concomitant chemoradiotherapy with platinum-based chemotherapy (CLRT <sub>P</sub> ) was 0·82 (95% CI 0·66-1·01) for overall survival. The superiority of HFCRT was robust to sensitivity analyses. Three other modalities of treatment had a better P score, but not a significantly better HR, for overall survival than CLRT <sub>P</sub> (P score 78%): induction chemotherapy with taxane, cisplatin, and fluorouracil followed by locoregional therapy (IC <sub>TaxPF</sub> -LRT; 89%), accelerated radiotherapy with concomitant chemotherapy (82%), and IC <sub>TaxPF</sub> followed by CLRT (80%).
The results of this network meta-analysis suggest that further intensifying chemoradiotherapy, using HFCRT or IC <sub>TaxPF</sub> -CLRT, could improve outcomes over chemoradiotherapy for the treatment of locally advanced head and neck cancer.
French Institut National du Cancer, French Ligue Nationale Contre le Cancer, and Fondation ARC.
We did a frequentist network meta-analysis based on individual patient data of meta-analyses evaluating the role of chemotherapy (Meta-Analysis of Chemotherapy in Head and Neck Cancer [MACH-NC]) and of altered fractionation radiotherapy (Meta-Analysis of Radiotherapy in Carcinomas of Head and Neck [MARCH]). Randomised, controlled trials that enrolled patients with non-metastatic head and neck squamous cell cancer between Jan 1, 1980, and Dec 31, 2016, were included. We used a two-step random-effects approach, and the log-rank test, stratified by trial to compare treatments, with locoregional therapy as the reference. Overall survival was the primary endpoint. The global Cochran Q statistic was used to assess homogeneity and consistency and P score to rank treatments (higher scores indicate more effective therapies).
115 randomised, controlled trials, which enrolled patients between Jan 1, 1980, and April 30, 2012, yielded 154 comparisons (28 978 patients with 19 253 deaths and 20 579 progression events). Treatments were grouped into 16 modalities, for which 35 types of direct comparisons were available. Median follow-up based on all trials was 6·6 years (IQR 5·0-9·4). Hyperfractionated radiotherapy with concomitant chemotherapy (HFCRT) was ranked as the best treatment for overall survival (P score 97%; hazard ratio 0·63 [95% CI 0·51-0·77] compared with locoregional therapy). The hazard ratio of HFCRT compared with locoregional therapy with concomitant chemoradiotherapy with platinum-based chemotherapy (CLRT <sub>P</sub> ) was 0·82 (95% CI 0·66-1·01) for overall survival. The superiority of HFCRT was robust to sensitivity analyses. Three other modalities of treatment had a better P score, but not a significantly better HR, for overall survival than CLRT <sub>P</sub> (P score 78%): induction chemotherapy with taxane, cisplatin, and fluorouracil followed by locoregional therapy (IC <sub>TaxPF</sub> -LRT; 89%), accelerated radiotherapy with concomitant chemotherapy (82%), and IC <sub>TaxPF</sub> followed by CLRT (80%).
The results of this network meta-analysis suggest that further intensifying chemoradiotherapy, using HFCRT or IC <sub>TaxPF</sub> -CLRT, could improve outcomes over chemoradiotherapy for the treatment of locally advanced head and neck cancer.
French Institut National du Cancer, French Ligue Nationale Contre le Cancer, and Fondation ARC.
Mots-clé
Chemoradiotherapy, Dose Fractionation, Radiation, Female, Head and Neck Neoplasms/mortality, Head and Neck Neoplasms/therapy, Humans, Male, Network Meta-Analysis
Pubmed
Web of science
Création de la notice
26/04/2021 12:08
Dernière modification de la notice
14/03/2023 6:49
Données d'usage
